J o u r n a l o f t h e A m e r i c a n P h a r m a c i s t s
need for evaluation of drug-drug interaction software
The pharmacist is seen as a primary line of defense for the prevention of potential drug-drug interactions (DDIs). During the previous 20 years, pharmacy systems have evolved to integrate drug knowledge databases with clinical information, performing a number of prospective evaluations (e.g., DDIs, drug-allergy checks, drug-disease interactions) during the dispensing process. Computerized screening for DDIs and other potential drug-related problems are incorporated within most pharmacy computer systems.
Despite the opportunity to identify potential DDIs, research suggests that pharmacy DDI screening programs perform suboptimally. [1] [2] [3] [4] In 1996, Cavuto et al. 1 evaluated the effectiveness of pharmacists and their computerized screening methods to intercept two prescriptions that were contraindicated (terfenadine and ketoconazole). Of the 50 pharmacies evaluated in the Washington, DC, area, 48 had computerized DDI screening but one-third dispensed the pair of prescriptions. Hazlet et al. 2 reviewed the performance of nine community pharmacy systems in screening for 16 well-established DDIs and found that one-third of DDIs were not detected. These nine systems were used in more than 500 community pharmacies in Washington State, which suggested that thousands of patients could be exposed to potentially harmful DDIs that were missed by computerized DDI screening programs. In 2006, Abarca et al. 3 reported on the ability of eight community pharmacies and five hospital pharmacies in the Tucson, AZ, metropolitan area to identify DDIs. They found that the median sensitivity was 0.88 (i.e., 88% of DDIs were detected) and 0.38 (i.e., 38% of DDIs were detected) among the community and hospital pharmacy systems, respectively. For the community pharmacies, this was an improvement from the findings of Hazlet et al. (median sensitivity 0.69). However, for the hospital systems, the findings indicated that the majority of DDIs presented would be missed. In a national survey, the Institute for Safe Medication Practices (ISMP) asked 190 hospital pharmacists to assess the ability of their computer systems to detect important DDIs. 4 When a contraindicated medication combination (i.e., rifampin and saquinavir) was entered into these pharmacy systems, 26% failed to identify the interaction.
Purpose of the ddi evaluation tool
The purpose of this tool is to (1) assess the performance of DDI software programs currently used in community and hospital pharmacies and (2) identify opportunities for improvement.
drug pairs included in the ddi evaluation tool
Researchers designed 18 test medication orders ( Table 1) that can be entered into a "test patient" profile in a pharmacy computer system. The test orders were developed to evaluate a total of 19 drug pairs. Of the 19 drug pairs, 13 are well-documented, clinically important interactions and 6 are noninteracting combinations. The clinically important DDIs to be analyzed in this study appear in Table 2 , and the six noninteracting combinations are listed in Table 3 .
The selected interacting medications were those deter-
At a Glance
Synopsis: Adverse drug interactions are preventable medication errors that must be addressed at multiple levels within the health care system. Pharmacists rely on clinical decision support (CDS) systems to assist in the identification of drug-drug interactions (DDIs). This report provides a tool that pharmacists can use to assess the CDS program in their practice environment.
Analysis Abbreviations used: CYP, cytochrome P450; DDI, drug-drug interaction; GI, gastrointestinal; INR, international normalized ratio; NSAID, nonsteroidal anti-inflammatory drug; PGP, P-glycoprotein; PPI, proton pump inhibitor. with an emphasis on commonly used 6 cardiovascular medications and those with potentially important adverse effects (e.g., warfarin). Using a process similar to previous research, 5 an evidence-based summary was developed for each of the 13 DDIs following a review of the primary and tertiary (compendia) [7] [8] [9] [10] literature to assess evidence and ascertain the potential for adverse clinical consequences (e.g., bleeding, rhabdomyolysis). Agreement of DDI importance or severity among the compendia was not a requirement for selection of DDIs because considerable disagreement exists among commonly used DDI references. [11] [12] [13] [14] [15] [16] The authors used compendia that were readily available, although several other DDI information resources are available for such purposes. Similarly, the absence of an interaction for the remaining drug pairs was verified in the same fashion.
Readers should note that the drug pairs chosen for this tool represent a selected set of all possible clinically relevant DDIs. The table is not intended to represent a list of the most important DDIs and can be adapted to address regional-, setting-, and pharmacy-specific quality assurance needs.
Benefits for pharmacy practice
Effective pharmacist-targeted interventions concerning DDIs have the potential to reduce the prevalence of adverse DDIs. To be useful to pharmacists, computer decision support programs should be sensitive and specific. In addition to evaluating pharmacy DDI software performance, this study also focused on potential ways to improve the ability of these systems to accurately and precisely identify clinically important DDIs.
Previous use of the ddi evaluation tool
The DDI evaluation tool was used in a study involving 64 pharmacies in Arizona. 17 Although study results were described in detail elsewhere, noting that the tool has proven useful in large and small community chain pharmacies, community independent pharmacies, hospital pharmacies, governmental facility pharmacies, and a host of others is important. The tool is sensitive enough to discern differences within and between chain pharmacies. Results may vary per setting, as would be expected because of the inconsistencies between DDI compendia [11] [12] [13] [14] [15] [16] and variability in the performance of DDI clinical decision support (CDS) systems. 2, 3, [17] [18] [19] [20] However, the intent of publishing Each drug pair to be tested is listed alphabetically in column A as the object drug (the drug affected by the interaction) + precipitant drug (the drug causing the interaction). The clinically important DDIs are listed first (items 1-13), followed by the noninteracting drug pairs (items [14] [15] [16] [17] [18] [19] . The correct software response is listed in column B (alert/no alert). For each pair, indicate whether the correct response was produced in column C (yes/no). The severity level of the alert is not important for this evaluation, only whether an alert is produced.
Tools ASSESSING PHARMACy DDI SOFTWARE the tool is to increase pharmacists' understanding and awareness of the functionality of the DDI software they use routinely. The tool is not intended to supplant the clinical judgment of the pharmacist but rather to inform the pharmacist concerning system functionality. It is hoped that this increased knowledge of system performance will help to better inform pharmacists' clinical decisions and lead to discussions with appropriate parties concerning system improvement. The tool can be adapted for individual pharmacy needs (e.g., acute care or pediatric medications).
steps for conducting an assessment of computerized ddi screening
Follow the steps listed below to conduct an evaluation of your pharmacy DDI computer system.
step 1: create a test patient profile
Create a test patient profile in the medication order entry system. Ensure that the test patient profile is appropriately interfaced so the capabilities are exactly the same as with an active patient profile. Of important note, use a test patient only and not an active patient profile, in order to ensure that the unsafe medication orders created during this assessment are not processed for an active patient profile and accidently dispensed. For the purposes of this evaluation, the medications can be entered in any order. If multiple products are available, select the one most frequently dispensed by your pharmacy.
step 2: complete the data collection form while entering test medication orders Enter the test medication orders that appear in Table 1 into the test patient profile. As the test medication orders are entered, record on the DDI alert data collection form (Table 4) whether your computer system provided an alert about the drug pairs of interest. The outcome of interest is whether an alert is generated for the drug pairs of interest. If it is of interest, consider recording the severity level of the interaction if one is provided. The CDS may create additional alerts, such as DDIs (e.g., amiodarone and clarithromycin) or therapeutic duplications (e.g., pravastatin and simvastatin); however, alerts for these nontargeted drug combinations are not the focus of this evaluation.
step 3: Assess the software responses
Tally the correct and incorrect responses for interacting and noninteracting drug pairs to determine whether false-positive or -negative alerts were generated (Table 4 , cells E, F, H, I, K, and L).
step 4 (optional): calculations
Using Figure 1 , calculate the percentage of correct responses and the sensitivity, specificity, positive predictive value, and negative predictive value of your system to classify each drug pair correctly. Each of these terms is explained in Figure 1 .
Compare your values to the reference values given in Figure  1 . Tally the responses and determine your pharmacy's overall There are a total of 19 drug pairs of interest. Thirteen drug pairs were clinically important DDIs, and 6 were noninteracting drug combinations. The overall performance of your pharmacy's DDI software can be evaluated using five measures: percent of correct responses, sensitivity, specificity, positive predictive value, and negative predictive value. Definitions and formulas are listed below. Calculations • Percentage of correct responses is calculated as follows: (number of correct responses)/(number of drug pairs evaluated). So, using the data collection form (Table 4) , this is (total in cell K)/(19) ¥ 100.
• Sensitivity is the probability of a DDI alert given that a clinically important DDI is present and is calculated as follows: (number of truepositive DDI alerts)/(number of clinically important DDI pairs). So, using the data collection form (Table 4) , this translates to (total in cell E)/(13).
• Specificity is the probability of the absence of an alert given that a DDI is not present and is calculated as follows: (number of truenegative nonalerts)/(number of non-DDI pairs). Using Table 4 , this calculation can be performed as (total in cell H)/(6).
• Positive predictive value (PPV) is a measure of the usefulness of the alert in that it is the probability that a DDI alert represents a true DDI: PPV = (number of true positives)/(number of true positives + number of false positives). Using Table 4 , this calculation can be performed as (total in cell E)/(total in cell E + total in cell I).
• Negative predictive value (NPV) is the probability that the absence of a DDI alert represents a true absence of a DDI: NPV = (number of true negatives)/(number of true negatives + number of false negatives). Using Table 4 , this calculation can be performed as (total in cell H)/(total in cell H + total in cell F). ASSESSING PHARMACy DDI SOFTWARE Tools performance. In addition, you may wish to examine in greater detail why some interactions were not identified. Try different strengths or different manufacturers, package sizes, and dosage formulations. A well-functioning CDS will identify all 13 well-established interactions.
step 5: consider general and specific system improvements General computer software recommendations are included in Tables 2, 3 , and 5.
step 6: share information ■ Make others aware of the results of your analysis, specifically management, other pharmacists and personnel, computer software vendors, and those responsible for computer software performance. Use the results of this analysis to suggest changes to and improvements in the system. ■ Learn more about these specific clinically important DDIs, including potential management strategies (Table 2) . ■ Insist that all pharmacists and technicians are trained on how the CDS software generates alerts for DDIs. Knowing the system's capabilities is important. If over-thecounter medications or medications from another pharmacy are added to the patient profile, are these medications checked by the DDI system? Understanding which alerts are suppressed (if any), how the system categorizes alerts, how to find additional information on DDI mechanism of action and management, and how to document interventions is important. ■ Review your facilities' policies and procedures for how to handle DDI alerts. Assess places in the order entry and dispensing process in which quirks or gaps in the pharmacy software or workflow may be contributing to missed alerts. A specific safety concern exists in pharmacies where technicians or interns enter medication orders. The checking pharmacist may not know about alerts that were displayed but bypassed during the order entry process.
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If your pharmacy software automatically prints hard copy alerts for pharmacist review, rather than pharmacists reviewing on the computer, test the system to ensure that all alerts are printed and checked by a pharmacist. During an evaluation of alerts from one chain pharmacy's software system, we observed that some DDI alerts failed to print automatically, which conflicted with pharmacist expectations of the system. Consequently, missing interactions would be easy. Such an example underscores the importance of pharmacy technician training about procedures for handling DDI alerts and the need for vigilance on the part of every pharmacy employee. We recommend making it impossible for order entry technicians to bypass important alerts. Instead, these orders should remain in a queue for release by a pharmacist after viewing and responding to the associated problem. 21 If a pharmacist eventually bypasses a high-priority alert, document the reason so that it can be evaluated in quality improvement activities. ■ Educate all pharmacy staff members, including technicians and interns, about the importance of detecting DDIs and following proper policies and procedures to ensure that pharmacists review all clinically important DDIs before dispensing. Along with pharmacists, technicians also play a vital role in protecting the general public from potential DDIs. Personal interaction with patients affords pharmacy technicians the opportunity to ask patients whether they currently use medications from other pharmacies or use over-the-counter medications, including herbal remedies, and to update patients' medication profiles accordingly.
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■ Evaluate frequently bypassed alerts for ways to improve the systems' sensitivity and specificity. For example, eliminate irrelevant DDI alerts that are generated for certain topical medications. Another option is to identify highpriority drug combinations that contribute to the most serious potential adverse drug events, and use the list to limit and customize DDI alerts or to serve as a resource for pharmacists who are checking orders.
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■ Get involved in pharmacy quality improvement initiatives at the pharmacy, company, state, or national levels (e.g., ISMP, PQA [the Pharmacy Quality Alliance]). Pharmacists also should familiarize themselves with the current settings of the pharmacy's DDI software. Knowing how the DDI software classifies DDI alerts (e.g., mild, moderate, severe) and whether certain "levels" have been suppressed or "turned off" may help prevent missing important interactions.
Abbreviation used: DDI, drug-drug interaction.
Tools ASSESSING PHARMACy DDI SOFTWARE conclusion Pharmacists can use the evaluation tool available in this article to assess the performance of their DDI software programs, identify areas for improvement, suggest improvements, and begin a dialog with key personnel on how to implement changes to pharmacy software systems and internal procedures regarding the prevention of DDIs. Assessing the software also creates the opportunity to evaluate inadequacies in policies, procedures, workflow, and training of all pharmacy staff relating to DDIs. Adverse drug interactions are preventable medication errors that must be addressed at multiple levels within the health care system. 
